Reports and industry briefings.
Explore current perspectives across pharma, MedTech, market access, and care delivery. Search by topic, therapy area, audience, or strategic question.
Why heart failure management is hard when congestion, comorbidity, discharge timing, medication optimization, and early follow-up all move at once.
U.S. prevalence, mortality, readmissions, aging, HFpEF, and multimorbidity frame HF as a chronic-care and transition-of-care problem.
OSA care shifts from lab-based diagnosis toward home testing, virtual setup, device coaching, and longitudinal adherence management.
How diagnostic access, device setup, mask fit, and adherence support change the sleep apnea treatment pathway.
Why primary knees fail and need revision when infection, loosening, instability, stiffness, fracture, wear, or malalignment changes the pathway.
How the same diagnosis can lead to different treatment journeys when access, support, and risk differ.
Why AF pathways depend on detection yield, stroke risk, symptom burden, anticoagulation decisions, rhythm strategy, and clean handoff to longitudinal care.
AF care shifts from incidental detection and remote monitoring to primary care, cardiology, electrophysiology, and longitudinal anticoagulation support.
Projected prevalence, age-linked risk, hospitalizations, silent disease, and anticoagulation handoffs frame AFib as a population-scale rhythm-management problem.
Monitoring yield, anticoagulation decisions, rhythm care, stroke prevention, and specialist access shape the AF market.
Why metabolic surgery depends on selection, access, procedure fit, perioperative risk, and lifelong surveillance.
Why a foot ulcer can become a limb-threatening episode when neuropathy, ischemia, infection, offloading, wound care, and follow-up all have to align.
How connected surgical environments create adoption risk across clinical, IT, and commercial stakeholders.
DFU care shifts between primary care, wound center, vascular lab, hospital, and home as infection, ischemia, and offloading needs change.
A high-risk limb-preservation market shaped by chronic burden, slow healing, recurrence, infection, vascular disease, and coordinated care.
A high-risk diabetes complication creates clinical and economic burden when neuropathy, PAD, infection, and follow-up gaps delay healing.
Why one study rarely persuades every clinical, economic, and operational audience the same way.
A reusable funnel for seeing where clinically eligible patients fall out before therapy becomes sustained behavior.
Admissions, discharge risk, medication optimization, remote monitoring, and post-acute coordination shape heart failure value capture.
A life-science tour of how drug classes, monitoring, implantable devices, and advanced therapies map to HF phenotypes, risk, and care goals.
How connected devices, follow-up capacity, and home support change the post-discharge heart failure pathway.
Metabolic care shifts across primary care, specialty obesity programs, bariatric surgery, pharmacy, digital coaching, and long-term monitoring.
Medication access, bariatric pathways, diabetes risk, sleep apnea adjacency, and follow-up infrastructure shape metabolic-care value capture.
Large cardiometabolic populations create demand across obesity treatment, diabetes prevention, sleep apnea, cardiovascular risk, and durable follow-up support.
Undiagnosed sleep-disordered breathing creates downstream risk across cardiovascular disease, metabolic health, daytime function, and device-adherence workflows.
Diagnosis access, home testing, PAP adherence, oral devices, cardiometabolic risk, and payer interest shape OSA value capture.
How monitoring duration, workflow follow-through, and access change whether intermittent AF becomes an actionable signal.
PAD care shifts from primary care and vascular testing to specialist intervention, wound programs, and surveillance as limb risk escalates.
PAD prevalence, age distribution, symptom status, diabetes-related foot ulcer overlap, and limb outcomes help describe the clinical burden of lower-extremity arterial disease.
How PAD risk escalates from exertional symptoms to chronic limb threat when vascular testing, referral, revascularization, wound risk, and surveillance fragment.
Why failed primary THA requires failure-mode diagnosis before teams choose fixation, stability, infection, metal-debris, and recovery pathways.
How early wound assessment, offloading, vascular checks, and home support can change the diabetic foot pathway.
How the same hip replacement indication can lead to different recovery paths when fracture risk, home support, comorbidities, and post-acute access differ.
How symptom recognition, vascular testing, referral timing, and surveillance change the peripheral artery disease pathway.
How obesity and metabolic disease care diverges when medication access, comorbidities, coaching support, and long-term monitoring differ.
How early-career training aligns clinical trust, compliance, scalable delivery, and measurable skill transfer.
Detection access, monitoring yield, stroke prevention, rhythm-care capacity, and longitudinal adherence reinforce the AF care market.
Diabetes prevalence, ulcer recurrence, limb preservation, wound-care innovation, vascular coordination, and value pressure reinforce DFU market demand.
Medication access, bariatric pathways, diabetes prevention, sleep apnea adjacency, and long-term follow-up reinforce metabolic-care demand.
Diagnosis expansion, home testing, device adherence, cardiometabolic risk management, and payer interest reinforce the sleep apnea market.
Earlier detection, vascular referral, revascularization capacity, wound prevention, and limb-preservation economics reinforce PAD market demand.
Aging demand, OA burden, fracture complexity, outpatient execution, implant innovation, and revision prevention reinforce hip arthroplasty market demand.
Demand, technology, outpatient execution, and revision prevention reinforce the U.S. knee arthroplasty market.
Diagnosed arthritis, osteoarthritis, age, length of stay, fixation patterns, and revision causes help describe the population-level burden associated with total hip arthroplasty.
Hip arthroplasty moves across inpatient, outpatient, and ASC settings as patient selection, fracture complexity, and recovery support diverge.
Diagnosed arthritis, osteoarthritis, obesity, age, site of care, and revision causes help describe the population-level burden associated with total knee arthroplasty.
The market is growing, but the bigger shift is where care happens and who captures value.
Hip reconstruction demand, outpatient migration, fracture-related complexity, implant economics, and revision care shape the THA market.
A million-procedure-scale market shaped by demand, site-of-care migration, device revenue, enabling technology, and revision risk.
How a hospital value committee pressure-tests orthopaedic innovation before adoption.
Use the care reality around each population to decide where education, access support, and follow-up can actually land.
AF detection, rhythm-monitoring access, diagnostic yield, and therapy-handoff visuals.
Diabetic foot ulcer market burden, limb preservation, vascular risk, recurrence, and care-delivery visuals.
Heart failure discharge, remote monitoring, early signal detection, and post-acute care visuals.
Obesity, metabolic surgery, GLP-1-adjacent populations, diabetes, cardiometabolic risk, and longitudinal follow-up visuals.
OSA device access, CPAP adoption, sleep-disordered breathing risk, and metabolic-care adjacency visuals.
TKA market structure, site-of-care movement, revision complexity, technology education, and recovery visuals.
PAD workup, diabetic limb risk, vascular triage, and limb-preservation pathway visuals.
THA epidemiology, opportunity sizing, revision, fracture-related arthroplasty, and hip reconstruction care-pathway visuals.